摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

异硫氰酸3-氯-2-甲基苯基 | 19241-35-1

中文名称
异硫氰酸3-氯-2-甲基苯基
中文别名
3-氯-2-甲基苯基异硫氰酸酯
英文名称
1-chloro-3-isothiocyanato-2-methylbenzene
英文别名
2-methyl-3-chlorophenyl isothiocyanate;3-Chloro-2-methylphenyl isothiocyanate;3-chloro-2-methyl-phenyl isothiocyanate;3-Chlor-2-methyl-phenylisothiocyanat;1-chloro-3-isothiocyanato-2-methyl-benzene
异硫氰酸3-氯-2-甲基苯基化学式
CAS
19241-35-1
化学式
C8H6ClNS
mdl
MFCD00022056
分子量
183.661
InChiKey
ZXEZATIRZLJXFU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    99 °C(Press: 2-3 Torr)
  • 密度:
    1.18±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    44.4
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 安全说明:
    S26,S36,S37/39
  • 危险类别码:
    R20/21/22,R36/37/38
  • 海关编码:
    2930909090
  • 危险品标志:
    Xn
  • 危险品运输编号:
    UN2810
  • WGK Germany:
    1
  • RTECS号:
    JR2450000

SDS

SDS:d3991e4f067d058df5a788ca6f7365fd
查看
Name: 3-Chloro-2-methylphenyl isothiocyanate 97% Material Safety Data Sheet
Synonym:
CAS: 19241-35-1
Section 1 - Chemical Product MSDS Name:3-Chloro-2-methylphenyl isothiocyanate 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
19241-35-1 3-Chloro-2-methylphenyl isothiocyanate 97% unlisted
Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye irritation. Lachrymator (substance which increases the flow of tears).
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under nitrogen.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 19241-35-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless - pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H6ClNS
Molecular Weight: 184

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Bases, oxidizing agents, reducing agents, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 19241-35-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Chloro-2-methylphenyl isothiocyanate - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
IMO
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
RID/ADR
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 19241-35-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 19241-35-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 19241-35-1 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    异硫氰酸3-氯-2-甲基苯基 作用下, 以 甲醇 为溶剂, 反应 12.0h, 生成 1-(3-氯-2-甲基苯基)-2-硫脲
    参考文献:
    名称:
    Synthesis of thiophene-2-carboxamidines containing 2-amino-thiazoles and their biological evaluation as urokinase inhibitors
    摘要:
    The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino- 1,3-thiazolyl]-thiophene-2-carboxamidine is described. Further optimization of this series by substitution of the terminal amine yielded urokinase inhibitors with excellent activities. (C) 2001 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(01)00102-0
  • 作为产物:
    描述:
    methyl N-(3-chloro-2-methylphenyl)carbamodithioate 在 mercury(II) oxide 作用下, 以 乙醚 为溶剂, 反应 1.0h, 生成 异硫氰酸3-氯-2-甲基苯基
    参考文献:
    名称:
    Synthesis of 2-Aryliminoimidazolidines and 2-Arylaminobenzimidazoles from MethylN-Aryldithiocarbamates
    摘要:
    DOI:
    10.1055/s-1982-29846
点击查看最新优质反应信息

文献信息

  • 2-Imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P<sub>1</sub>Receptor Agonists
    作者:Martin H. Bolli、Stefan Abele、Christoph Binkert、Roberto Bravo、Stephan Buchmann、Daniel Bur、John Gatfield、Patrick Hess、Christopher Kohl、Céline Mangold、Boris Mathys、Katalin Menyhart、Claus Müller、Oliver Nayler、Michael Scherz、Gunther Schmidt、Virginie Sippel、Beat Steiner、Daniel Strasser、Alexander Treiber、Thomas Weller
    DOI:10.1021/jm100181s
    日期:2010.5.27
    through five specific G-protein coupled receptors numbered S1P1 through S1P5. Agonists of the S1P1 receptor block the egress of T-lymphocytes from thymus and lymphoid organs and hold promise for the oral treatment of autoimmune disorders. Here, we report on the discovery and detailed structure−activity relationships of a novel class of S1P1 receptor agonists based on the 2-imino-thiazolidin-4-one scaffold
    鞘氨醇-1-磷酸酯(S1P)是一种广泛的溶血磷脂,具有丰富的生物学效应。细胞外S1P通过五个特定的G蛋白偶联受体S1P 1至S1P 5传递其活性。S1P 1受体激动剂阻止T淋巴细胞从胸腺和淋巴器官流出,并有望用于自身免疫性疾病的口服治疗。在这里,我们报告的发现和详细的结构与活性之间的关系基于2-亚氨基-噻唑烷酮-4-酮骨架的新型S1P 1受体激动剂。化合物8bo(ACT- 128800)从该系列中出现,是一种有效的,选择性的,口服活性的S1P 1选择受体激动剂进行临床开发。在大鼠中,以3 mg / kg的剂量达到最大程度的循环淋巴细胞减少。淋巴细胞隔离的持续时间是剂量依赖性的。在100 mg / kg的剂量下,对淋巴细胞计数的影响在不到36小时内是完全可逆的。8bo在比格犬中的药代动力学研究表明,该化合物适合于人类每天一次给药。
  • Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
    申请人:Bayer Corporation
    公开号:US06353006B1
    公开(公告)日:2002-03-05
    This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.
    这项发明涉及2-芳基亚胺杂环化合物,包括2-芳基亚胺-1,3-噻唑啉、2-芳基亚胺-2,3,4,5-四氢-1,3-噻嗪、2-芳基亚胺-1,3-噻唑啉-4-酮、2-芳基亚胺-1,3-噻唑啉-5-酮和2-芳基亚胺-1,3-噁唑啉,以及它们在调节孕激素受体介导的过程中的应用,以及用于这类治疗的药物组合物。
  • [EN] 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES<br/>[FR] DÉRIVÉS DE 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE
    申请人:BAYER AG
    公开号:WO2020216774A1
    公开(公告)日:2020-10-29
    Compounds of formula (I) for use in the treatment or prophylaxis of a disease, which is a hyperproliferative disease and/or a disorder responsive to induction of cell death, selected from a haematological tumour, a solid tumour and/or metastases thereof, said tumour harbouring a mutant EGFR with exon 19 or 21 mutations, and their use as pharmaceuticals.
    式(I)的化合物用于治疗或预防一种高增殖性疾病和/或对诱导细胞死亡敏感的疾病,所述疾病选自血液肿瘤、实体肿瘤和/或其转移瘤,所述肿瘤携带具有外显子19或21突变的突变EGFR,并将其用作药物。
  • 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives for
    申请人:American Home Products Corporation
    公开号:US05599829A1
    公开(公告)日:1997-02-04
    A method for increasing blood serum HDL cholesterol levels in a mammal in need of increased HDL cholesterol blood serum levels, which comprises administering to said mammal, an effective amount of a compound of formula I: ##STR1## wherein R is phenyl or phenyl optionally substituted with one or more groups selected from halogen, alkyl, perfluoroalkyl, alkoxy, perfluoroalkoxy, hydroxy, alkanoyloxy, aroyloxy or arylalkanoyloxy; R.sup.3 is alkyl, aryl or arylalkyl; or a pharmaceutically acceptable salt thereof.
    一种用于增加需要增加高密度脂蛋白胆固醇血清水平的哺乳动物血清中高密度脂蛋白胆固醇水平的方法,包括向所述哺乳动物施用化合物I的有效量:##STR1##其中R是苯基或苯基,可选地取代为来自卤素、烷基、全氟烷基、烷氧基、全氟烷氧基、羟基、烷酰氧基、芳酰氧基或芳基烷酰氧基的一个或多个基团;R.sup.3是烷基、芳基或芳基烷基;或其药学上可接受的盐。
  • Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of
    申请人:American Home Products Corporation
    公开号:US05554607A1
    公开(公告)日:1996-09-10
    A method for increasing the HDL cholesterol concentration in the blood of a mammal in need of increased HDL cholesterol blood concentration, which comprises administering to said mammal, orally or parenterally, a compound of formula I: ##STR1## wherein R is alkyl; a substituted or unsubstituted aromatic N, O or S heterocycle; substituted or unsubstituted aryl, arylalkyl, benzhydryl or indanyl, in which the substituents are one to three members independently selected from the group consisting of alkyl, alkoxy, alkylthio, alkenyl, alkynyl, halo, perfluoroalkyl, perfluoroalkyl or hydroxy; and R.sup.1 is aryl, alkyl, alkenyl, alkynyl or substituted aryl where the substituents are one to three members independently selected from the group consisting of alkyl, alkoxy, alkylthio, alkenyl, alkynyl, halo, perfluoroalkyl, perfluoroalkoxy or hydroxy.
    一种用于增加需要增加高密度脂蛋白胆固醇血浓度的哺乳动物血液中HDL胆固醇浓度的方法,包括向所述哺乳动物口服或静脉注射化合物I的步骤:##STR1##其中R为烷基;取代或未取代的芳香族N、O或S杂环;取代或未取代的芳基、芳基烷基、苯基甲基或茚基,在其中取代基是从烷基、烷氧基、烷硫基、烯基、炔基、卤素、全氟烷基、全氟烷基或羟基组成的群中独立选择的一到三个成员;以及R.sup.1为芳基、烷基、烯基、炔基或取代芳基,其中取代基是从烷基、烷氧基、烷硫基、烯基、炔基、卤素、全氟烷基、全氟烷氧基或羟基组成的群中独立选择的一到三个成员。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐